Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms

Researchers investigate the effects of high-dose fluvoxamine among patients with mild-to-moderate COVID-19.

FDA Expands Approval of RSV Vaccine Abrysvo to Include All At-Risk Adults

The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower respiratory tract disease (LRTD) caused

October 24, 2024

MindBio Therapeutics Corp. Announces Completion of Landmark Phase 2A LSD Microdosing Clinical Trial in Distressive Disorder | Psychedelic Invest

MindBio Therapeutics Corp. announced it is nearing the completion of its Phase 2a clinical trial using MB22001 in patients with Major Depressive Disorder. MindBio reported

January 30, 2024

AvaSure Acquires Ouva’s Smart Room Solutions to Enhance AI-Powered Virtual Care Platform

What You Should Know: – AvaSure, a provider of acute virtual care, announced today the acquisition of Ouva’s smart room solutions. This strategic move aims

July 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.